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To the Editor, 
  
We would like to thank Antonio Sarria-Santamera for the interest shown in our article1. In his 
letter, he raises 2 different issues.  
First, he mentions limitations in interpreting the hazard ratio. However, these limitations are 
inherent in the estimator and do not depend on whether the study is experimental or not and, 
consequently, would not be mitigated by a different study design2. 
Second, he mentions the causal relationship between implementation of the PROGALIAM 
program and the decrease in mortality. The ideal context for this kind of inference is a clinical trial, 
but conducting a trial would not have been ethical in view of the nature of the study. As he points 
out, the alternative is to find a comparable group around the same timeframe. In the case of the 
IPHENAMIC program, this was not possible because the PROGALIAM network was established 
simultaneously throughout the geographical area, which precluded application of some of the 
methods proposed. Other alternatives, such as propensity score matching, are not desirable because 
they start with the effect thatthe intervention could influence the profile of patients arriving atthe 
hospital alive, and this effect should not be cancelled out. The plausibility of causal effects between 
PROGALIAM implementation and reduced mortality is supported by the survival analysis and by 
observations such as the fact that 30-day gross mortality before PROGALIAM was almost 
unchanged and began to decline after implementation, as shown in figure 2 of our article1. Likewise, 
figure 1 of the additional material shows that 30-day mortality in the total population and in each of 
the areas dropped significantly, particularly in areas where access improved to a greater extent. 
Although not impossible, it is highly unlikely that there are any variables not included in our study 
that coincided with PROGALIAM implementation and had sufficient impact on mortality to explain 
these findings.  
Despite the limitations of observational studies, we believe that they are essential in certain 
settings and, as expressed by the European Union and by the author himself in his references, are 
very useful for collecting real-world information, identifying outcomes, and ensuring responsible 
use of public funds3,4. 
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